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One of the pharmaceutical fields greatest challenges in
the next few years will be to create suitable, safe, and
well-functioning systems for electronic communication,
dissemination of information, and commerce. The sys-
tem would cover electronic prescribing and dispensing,
e-commerce of medicines, marketing and dissemination
of drug information in the Internet, and access to elec-
tronic services in pharmaceutical matters for consumers
and businesses alike. The development of information
technology and international examples are stimulating
this process.
Interested individuals and IT-companies have taken
the initiative in developing systems associated with elec-
tronic prescribing and dispensing in Finland.  As a by-
stander, it seems to me that the basic framework and
conditions applicable to health and medical services,
within which e-prescriptions should function, have been
forgotten.  The system must at least take into account
data protection, the rights of patients, pharmacovigi-
lance, rational prescribing and the drug reimbursement
system. Furthermore, due to the nature of the business,
national coverage for the systems would be preferable.
It is excellent that the Ministry of Social Affairs and
Health has paid attention to these matters in connection
with the Satakunta Macro Pilot Study of Processing
Medicine Information. Accepting practical realities is al-
so useful. The sad truth is that the majority of doctors
working at Municipal Health Centres do not have ac-
cess to appropriate workstations.
E-commerce refers usually to commercial transac-
tions via the Internet. The concept could be broadened
to cover other modes of distance trading, such as orders
transmitted and processed via television and telephone.
Pressures to develop the e-commerce of medicines fur-
ther seem to emanate from the USA and the illicit
traders in pharmaceuticals in the Internet, whose trad-
ing and merchandise give rise to warnings in interna-
tional forums from time to time. 
The instructions issued by the World Health Organi-
sation (WHO) last year make up the most definitive and
cautionary set of advice issued so far on how to ap-
proach trading in medicines in the Internet. From a
Finnish point of view, it would be preferable that a con-
trolled system that takes into account the above men-
tioned aspects would be implemented. The possible need
for legislative reforms or amendments should be as-
sessed. It would seem natural that the actors in the
pharmaceutical field were in charge of this developmen-
tal work. The European Commission has only recently
appointed working groups to assess the potential need
for EU legislation or directives for the e-commerce of
medicines. One of the two working groups should take
a stand on the promotion of prescription medicines in
the Internet especially aimed at consumers, which is
allowed in the USA. 
The image of consumers and patients as passive re-
cipients of regulated information is now history. This
applies also to medicines. Today’s consumer is sophisti-
cated, aware of his rights, and willing to find informa-
tion on his own medication or to discover potential
drug therapies for himself. This situation has created
tremendous marketing potential, especially for the phar-
maceutical industry, not to mention the so-called portal
companies. As a medium, the Internet is virtually impos-
sible to control completely. It is therefore necessary to
find ways to ensure that impartial, validated informa-
tion on medicines, free from commercial interests, is
available.  The demand such information is constantly
growing even among health care professionals. EMEA
(The European Agency for the Evaluation of Medicinal
Products) and the authorities in many EU member states
already publish summaries of product charasteristics,
consisting of accepted and official drug characteristics,
and information packages describing correct drug usage.
The Finnish National Agency for Medicines will also
support this development.
According to reports in the press, it is typical that
enterprises relying on teenage coders and network ex-
perts are in the vanguard of developments among IT-
companies. It is therefore important that actors aware
of their responsibilities and competent supervisory au-
thorities lead the e-projects of the pharmaceutical and
medical fields. 
Hannes Wahlroos
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National Agency for Medicines
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The pathogenesis and pathophysiolo-
gy of the syndrome are poorly
known.  The clinical diagnosis is
based on the history and the tender-
ness found in anatomically pre-
dictable areas, which seem to reflect
the general distress and misery of the
individual.  Due to the multitude of
symptoms of FM, it is usual for the
patient to be labelled with several di-
agnoses that do not reflect the symp-
toms complained of by the patient or
the clinical findings, but which reflect
the specialisation of the doctor.
According to one British study,
over 40% of the adult population is
reported to suffer from chronic pain,
and according to another one, over
10% suffer from pervasive pain.  FM
can be diagnosed in 2–3% of the
population.  The majority of the pa-
tients are women, and, since only few
patients are cured, the frequency of
the syndrome increases with age.
Electrical activity of the brain
during sleep, neuro-endocrinological
disturbances and circulatory and
metabolic disturbances of the muscu-
lar system, deformities of connective
tissue, the individual’s lack of ability
to cope with conflicts and primary
psychiatric problems have, for exam-
ple, been offered as pathogenetic
mechanisms of fibromyalgia.  The de-
bate continues.
Treatment of fibromyalgia
Close co-operation between doctor
and patient is the main precondition
for planning individual treatment and
monitoring of follow-up.  Occasion-
ally the patient has acquired a good
deal of information and requests an
appointment with a specialist.  Only
an unbiased attitude, careful listening
to the patient and a thorough clinical
examination, together with a com-
prehensive account of the complex
character of the sensation of pain,
may enable the doctor to avoid ac-
quiescing to the referral in that situa-
tion.
The aim should be a prompt diag-
nosis without unnecessary exclusion
studies that only lead to a merry-go-
round of investigations.  However,
consideration should be given to the
causes of exhaustion which need to
be treated more specifically (anemia,
hypothyroidism, hyperparathyroi-
dism and estrogen deficiency) or
chronic pain (arthritis, polymyalgia).
It is often useful to listen to the pa-
tient’s own theories and review them
properly in the light of medical evi-
dence.  It is also important that the
doctor emphasises the functional
character of the symptoms and there-
by their benign character.  A severely
depressed patient should be referred
for psychiatric treatment.
There is no treatment which pro-
vides a cure and consequently the
aim of treatment should be to reduce
symptoms and improve the patient’s
ability to function and quality of life.
In the treatment of a fibromyalgic pa-
tient, all modes of treatment based
on medical evidence should be put
into practice immediately.  However,
a large number of patients will be
disappointed with the help that med-
ical science can give and will also
turn to alternative therapies; popular
forms include, for example, the use
of various diets, supplementary trace
elements, and also massage involving
the musculo-skeletal system, particu-
larly lymph therapy.
A social history is important be-
cause it will explain any conflicts
there are in the family circle or work
environment, the patient’s way of life,
sleep hygiene and hobbies.  It is rec-
ommended that the resources of the
occupational health services be used
to survey the patient’s occupational
ergonomics and working conditions.
Treatment without drugs
The physical condition of FM pa-
tients is usually poorer than that of
healthy volunteers, and it has been
possible to reduce patients’ symp-
toms and improve their performance
by physical training and muscle-
building exercises.  The patients are
also given information about fibro-
myalgia and its treatment, taught
pain treatment, creation of a positive
outlook, relaxation, meditation, yo-
ga, stretching exercises, etc.  Individ-
ual reports of relief of symptoms
have also been received with electri-
cal acupuncture, feedback exercises,
hypnotherapy and homoeopathy.
Treatment of fibromyalgia with
drugs - antidepressants used as
analgesics
Tricyclic antidepressants in small dos-
es (particularly amitriptyline, 10–50
mg/day) are used in the treatment of
FM.  The preparations in this group
of medical substances are most effec-
Fibromyalgia
The main characteristics of fibromyalgia (FM) are pain in the musculo-skeletal system, night sleep
without resulting relaxation, and inexplicable exhaustion immediately upon awakening.  The pa-
tients also suffer from psychosomatic, psychiatric, neurological and other symptoms difficult to
categorise.  Despite this, there are no objective findings in these patients.
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tive in improving sleep quality, and
reducing pain and exhaustion; but
their effect on sensitivity is minor.
Even though these drugs provide
some mild relief to the majority of
patients who tolerate them, they are
really helpful only in about one in
three patients.  A positive response is
generally found after 1–2 weeks of
treatment.
To reduce adverse reactions (such
as dry mouth and sedation), the ad-
ministration should be started with
as low a dose as possible.  The drug
can be taken periodically.  A less an-
ticholinergic tricyclic antidepressant
is more appropriate than amitripty-
line in some patients.
Cyclobenzaprine, which has a
structural resemblance to amitripty-
line, is mainly considered a muscle
relaxant but it also has a proven ben-
eficial effect on the symptoms of FM.
There are recent reports of benefi-
cial effects of venlafaxine, a sero-
tonin and noradrenaline re-uptake
inhibitor, on FM patients.  At this
stage, however, it is reasonable to
wait until research results of con-
trolled studies are made available.
Other medical treatment
Anti-inflammatory analgesics and
glucocorticoids have been found to
be equal to placebos in controlled
studies.  A compound of ibuprofen
and codeine was not found to be
more effective than a placebo in our
own study either.  According to evi-
dence-based information, anti-in-
flammatory analgesics should not be
used to treat pain caused by fibro-
myalgia.
In a cross-over controlled study
consisting of a small number of pa-
tients, intravenous tramadol relieved
the pain in FM patients better than
did a placebo.  According to prelimi-
nary reports, patients who were ran-
domly chosen to take tramadol with-
drew less often than volunteers tak-
ing a placebo, due to the relative in-
effectiveness of the drug under study.
In a study from which patients
with adverse reactions to tramadol
were excluded, the reduction in pain
on the active drug was superior to
that on the placebo.  However, a
compound of paracetamol and
codeine has been found to have an
equivalent effect to tramadol in the
treatment of patients with various
types of chronic pain such as fibro-
myalgia.
Primarily due to the risk of addic-
tion, benzodiazepines should be
avoided in the treatment of chronic
pain, even though one cross-over
study showed that patients on a com-
bination therapy of alprazolam and
ibuprofen experienced a significant
relief of pain in comparison with pa-
tients receiving a double placebo.
Sleep disturbance is one of the
predominant symptoms of FM,
which is why sleep aids are also used
in the attempt to relieve patients’
symptoms.  Both zopiclon and zolpi-
dem have been found to improve pa-
tients’ rate of falling asleep, quality
of sleep and exhaustion the following
day, but they have not been found to
have an effect on pain.
Symptoms of some FM patients
have been relieved successfully by
specific 5-HT3 receptor blockers (tro-
pisetron, ondansetron).  In a five-day
study on ondansetron, volunteers
were given 1,000 mg of paracetamol
daily.  Symptoms of the patients in
this group of volunteers actually be-
came worse during follow-up.
In a Norwegian study lasting for
8 weeks, a compound of paraceta-
mol, caffeine and carisoprodol was
found to reduce the symptoms of FM
patients.  Due to the significant re-
sponse in the placebo group, the re-
sponse of the patients on active ther-
apy was not substantially different
statistically from that of the volun-
teers.
Gammahydroxybutyrate is a nat-
ural metabolite of the central nervous
system which is believed to act as a
neurotransmitter and neuromodula-
tor.  Eleven patients in an open study
received 4.5 g of gammahydroxybu-
tyrate in the evening over a period of
four weeks, which was found to re-
duce pain and exhaustion at the
same time as the patients’ nocturnal
EEG findings were normalised.
Growth hormone is known to be
secreted mainly during deep sleep
and its concentration can be moni-
tored by measuring the concentration
of serum insulin type growth factor I.
Patients with reduced concentrations
were randomised to a 9-month
growth hormone or placebo therapy.
Active treatment relieved the pa-
tients’ symptoms and improved their
ability to function, but the response
disappeared after interruption in the
treatment.
Conclusion
FM is a pain syndrome which is com-
mon, obviously multi-etiological,
broad-spectrum with regard to its se-
riousness, inadequately understood
with regard to its pathogenesis and
which has very important conse-
quences for public health.  Further-
more, patients with the severest
symptoms frequently rely on the
health care services.  Increased re-
search evidence indicates that mecha-
nisms of CNS origin lead these pa-
tients to interpret as pain some sensa-
tions which healthy individuals intre-
pret as normal stimuli.
The treatment of patients with the
severest symptoms should be man-
aged on a multidisciplinary basis.
I have specifically noticed the particu-
lar importance of a personal nurse
and a physiotherapist but the help of
an occupational therapist, nutritionist
and psychologist can also be impor-
tant. Patients with extremely severe
symptoms should receive treatment
at centres with special expertise.
Some patients may benefit from
regular appointments with their doc-
tor.  However, there is no need to re-
view all the patient’s symptoms again
or to repeat the examinations just in
case, but the aim with follow-up vis-
its should be to support the patient in
his/her effort to follow the prescribed
treatment and rehabilitation pro-
gramme by giving positive feedback.
There is a contradiction between
the multitude of symptoms exhibited
by the patients and the small number
of objective findings.  Consequently
the patients’  symptoms are often be-
littled and the patients are cate-
gorised as either somatisers, or they
are assumed to be malingering to get
social benefits or to be suffering from
a psychological illness.  As the neuro-
chemical basis of somatisation is not
known, it cannot be treated specifi-
cally.  In the absence of a highly spe-
cific treatment, all the treatment
modes where efficacy is supported by
medical evidence should be intro-
duced immediately the syndrome is
diagnosed.
Translation Mervi Moisander
